More importantly, when the same supernatants were tested on MUC16-positive OVCAR3 ovarian cancer cells, the MUC16-targeted Meso64TR3 variant was most efficient, while TR3 had almost no appreciable bioactivity, similar to the YFP control (Fig 5D). Here, MUC16 is linked to ovarian carcinoma.